| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
122,563,000 |
| Market
Cap: |
6.37(B) |
| Last
Volume: |
8,264,325 |
Avg
Vol: |
8,241,969 |
| 52
Week Range: |
$26.88 - $108.06 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
138,093 |
288,980 |
461,958 |
926,280 |
| Total Sell Value |
$8,135,395 |
$19,867,810 |
$25,677,895 |
$46,442,456 |
| Total People Sold |
7 |
8 |
8 |
12 |
| Total Sell Transactions |
11 |
21 |
41 |
87 |
| End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Blum Robert I |
President & CEO |
• • – |
2017-07-03 |
4 |
AS |
$12.10 |
$60,693 |
D/D |
(5,000) |
84,885 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2017-06-01 |
4 |
AS |
$13.40 |
$68,093 |
D/D |
(5,000) |
89,885 |
|
- |
|
| Charpentier Bonnie |
SVP Regulatory & Compliance |
• – – |
2017-02-28 |
4 |
A |
$0.00 |
$35 |
D/D |
35,000 |
29,004 |
|
- |
|
| Charpentier Bonnie |
SVP Regulatory & Compliance |
• – – |
2017-02-28 |
4 |
D |
$10.60 |
$63,558 |
D/D |
(5,996) |
9,004 |
|
- |
|
| Cragg David |
SVP Human Resources |
• – – |
2017-02-28 |
4 |
A |
$0.00 |
$35 |
D/D |
35,000 |
48,018 |
|
- |
|
| Cragg David |
SVP Human Resources |
• – – |
2017-02-28 |
4 |
D |
$10.60 |
$63,685 |
D/D |
(6,008) |
28,018 |
|
- |
|
| Barbari Sharon Surrey |
EVP, Finance & CFO |
• – – |
2017-02-28 |
4 |
D |
$10.60 |
$77,560 |
D/D |
(7,317) |
40,323 |
|
- |
|
| Barbari Sharon Surrey |
EVP, Finance & CFO |
• – – |
2017-02-28 |
4 |
A |
$0.00 |
$19 |
D/D |
18,750 |
47,640 |
|
- |
|
| Mcdowell Caryn Gordon |
GC & Chief Compliance Officer |
• – – |
2017-02-28 |
4 |
A |
$0.00 |
$15 |
D/D |
15,000 |
18,581 |
|
- |
|
| Wolff Andrew A |
SVP & CMO |
• – – |
2017-02-28 |
4 |
A |
$0.00 |
$28 |
D/D |
27,500 |
47,255 |
|
- |
|
| Wolff Andrew A |
SVP & CMO |
• – – |
2017-02-28 |
4 |
D |
$10.60 |
$52,830 |
D/D |
(4,984) |
32,255 |
|
- |
|
| Schnieders Elisabeth |
Sr. VP, Business Development |
• – – |
2017-02-28 |
4 |
A |
$0.00 |
$33 |
D/D |
32,500 |
43,919 |
|
- |
|
| Schnieders Elisabeth |
Sr. VP, Business Development |
• – – |
2017-02-28 |
4 |
D |
$10.60 |
$53,700 |
D/D |
(5,066) |
23,919 |
|
- |
|
| Morgan Bradley Paul |
SVP Drug Discovery & Early Dev |
• – – |
2017-02-28 |
4 |
A |
$0.00 |
$35 |
D/D |
35,000 |
45,194 |
|
- |
|
| Morgan Bradley Paul |
SVP Drug Discovery & Early Dev |
• – – |
2017-02-28 |
4 |
D |
$10.60 |
$63,452 |
D/D |
(5,986) |
25,194 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2017-02-28 |
4 |
A |
$0.00 |
$55 |
D/D |
55,000 |
45,404 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2017-02-28 |
4 |
D |
$10.60 |
$102,089 |
D/D |
(9,631) |
15,404 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2017-02-28 |
4 |
D |
$10.60 |
$180,274 |
D/D |
(17,007) |
93,768 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2017-02-28 |
4 |
A |
$0.00 |
$105 |
D/D |
105,000 |
110,775 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2016-12-29 |
4 |
S |
$12.52 |
$16,600 |
D/D |
(1,326) |
35 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2016-12-28 |
4 |
S |
$12.31 |
$53,043 |
D/D |
(4,307) |
1,361 |
|
- |
|
| Schnieders Elisabeth |
Sr. VP, Business DevelopmentOf |
• – – |
2016-12-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
16,485 |
|
- |
|
| Mcdowell Caryn Gordon |
GC & Chief Compliance OfficerO |
• – – |
2016-05-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,810 |
|
- |
|
| Morgan Bradley Paul |
SVP Drug Discovery & Early Dev |
• – – |
2015-11-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
13,391 |
|
- |
|
| Gage L Patrick |
Director |
– • – |
2015-08-31 |
4 |
B |
$6.95 |
$6,950 |
I/I |
1,000 |
1,850 |
2.1 |
- |
|
1115 Records found
|
|
Page 29 of 45 |
|
|
0.84 (1.59%) 
